Medivir: Annual Report 2012

HUDDINGE, Sweden--(BUSINESS WIRE)-- Regulatory News:

Medivir (STO:MVIR-B) Annual Report 2012 is now available at the company's website: www.medivir.com.


Annual Report 2012 http://www.medivir.se/v4/images/pdf/2013/Medivir-ENG-web_0403.pdf

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.

Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland.

Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company's website: www.medivir.com

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people's lives.

This information was brought to you by Cision http://news.cision.com



Medivir
+46 8 407 64 30
http://www.medivir.com
info@medivir.se

or
Rein Piir
EVP Corporate Affairs & IR
+46 8 546 831 23
rein.piir@medivir.com

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:

The article Medivir: Annual Report 2012 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Investing in Startups

The lucrative and risky world of startups.

View Course »

Add a Comment

*0 / 3000 Character Maximum